This investigator-initiated, double-blind, placebo-controlled study (funded by the Gates Foundation and Alzheimer's Association) evaluates the safety and tolerability, biological activity, and preliminary efficacy of LD IL-2 in 38 patients with mild-to-moderate Alzheimer's disease (AD) over 30 weeks
Previously reported data from an open-label, proof-of-concept study in eight AD patients illustrated that treatment with LD IL-2 resulted in a statistically significant improvement in cognitive function relative to baseline and significant enhancement of Regulatory T cell (Treg) function and numbers
Phase 2 top line data on track to be reported in summer of 2024